Latest Period
Q4 2025
- Info
- Insider Trading
- Financials
- Holders
Security Snapshot
NovaBridge Biosciences - Ordinary Shares, par value $0.0001 per share (Including Ordinary Shares Underlying American Depository Shares) (NBP) Institutional Ownership
CUSIP: 44975P103
13F Institutional Holders and Ownership History from Q1 2020 to Q1 2026
Institutions Reporting
57
Shares (Excl. Options)
33,200,810
Price
$3.98
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.
- Type / Class
- Equity / Ordinary Shares, par value $0.0001 per share (Including Ordinary Shares Underlying American Depository Shares)
- Symbol
- NBP on Nasdaq
- Shares outstanding
- 265,214,861
- Price per share
- $2.46
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 33,200,810
- Total reported value
- $132,139,164
- % of total 13F portfolios
- 0%
- Share change
- +3,660,868
- Value change
- +$14,644,437
- Number of holders
- 57
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- NBP - NovaBridge Biosciences - Ordinary Shares, par value $0.0001 per share (Including Ordinary Shares Underlying American Depository Shares) is tracked under CUSIP 44975P103.
- 57 institutions reported positions in Q4 2025.
- 2 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 57 to 2 between Q4 2025 and Q1 2026.
- Reported value moved from $132,139,164 to $6,202.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 57 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 44975P103?
CUSIP 44975P103 identifies NBP - NovaBridge Biosciences - Ordinary Shares, par value $0.0001 per share (Including Ordinary Shares Underlying American Depository Shares) in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 44975P103:
Significant Owners of NovaBridge Biosciences - Ordinary Shares, par value $0.0001 per share (Including Ordinary Shares Underlying American Depository Shares) (NBP) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Everest Medicines Ltd | 16% | $90,577,645 | 42,524,716 | Everest Medicines Limited | 05 Aug 2025 | |||
| CBC Investment I-Mab Ltd | 12% | +11% | $121,227,193 | +$11,952,376 | 30,499,709 | +11% | Wei Fu | 29 Jan 2026 |
As of 31 Dec 2025, 57 institutional investors reported holding 33,200,810 shares of NovaBridge Biosciences - Ordinary Shares, par value $0.0001 per share (Including Ordinary Shares Underlying American Depository Shares) (NBP). This represents 13% of the company’s total 265,214,861 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of NovaBridge Biosciences - Ordinary Shares, par value $0.0001 per share (Including Ordinary Shares Underlying American Depository Shares) (NBP) together control 12% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| JANUS HENDERSON GROUP PLC | 3.2% | 8,436,641 | +5.6% | 0.02% | $33,577,831 |
| HHLR ADVISORS, LTD. | 2.3% | 5,980,568 | 0% | 0.77% | $23,802,661 |
| MORGAN STANLEY | 1.4% | 3,785,502 | +70% | 0% | $15,066,298 |
| Siren, L.L.C. | 1.1% | 3,000,000 | +157% | 0.36% | $11,940,000 |
| Point72 Asset Management, L.P. | 0.87% | 2,298,501 | +2872% | 0.01% | $9,148,034 |
| Ariose Capital Management Ltd | 0.51% | 1,363,515 | -20% | 1.8% | $5,426,790 |
| Candriam S.C.A. | 0.43% | 1,132,563 | 0% | 0.02% | $4,507,793 |
| Woodline Partners LP | 0.4% | 1,050,000 | 0% | 0.02% | $4,179,000 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 0.38% | 1,000,000 | -70% | 0.01% | $3,980,000 |
| MILLENNIUM MANAGEMENT LLC | 0.32% | 846,008 | +3668% | 0% | $3,367,112 |
| BARCLAYS PLC | 0.24% | 628,923 | +59% | 0% | $2,503,113 |
| BlackRock, Inc. | 0.23% | 618,347 | 0% | $2,461,021 | |
| Exome Asset Management LLC | 0.19% | 499,587 | -65% | 1% | $1,988,356 |
| AIHC Capital Management Ltd | 0.16% | 413,979 | 0% | 1.5% | $1,647,636 |
| STATE STREET CORP | 0.14% | 359,878 | +6.7% | 0% | $1,432,314 |
| Connor, Clark & Lunn Investment Management Ltd. | 0.07% | 191,714 | +17% | 0% | $763,022 |
| UBS Group AG | 0.07% | 181,776 | -38% | 0% | $723,468 |
| DIMENSIONAL FUND ADVISORS LP | 0.06% | 148,452 | +50% | 0% | $590,839 |
| GOLDMAN SACHS GROUP INC | 0.05% | 140,946 | -35% | 0% | $560,965 |
| XTX Topco Ltd | 0.05% | 140,867 | +95% | 0.01% | $560,651 |
| JPMORGAN CHASE & CO | 0.05% | 131,830 | -12% | 0% | $524,683 |
| Taikang Asset Management (Hong Kong) Co Ltd | 0.05% | 128,765 | 0.05% | $512,485 | |
| BNP PARIBAS FINANCIAL MARKETS | 0.04% | 116,705 | 0% | 0% | $464,486 |
| ALPS ADVISORS INC | 0.04% | 112,451 | +0.86% | 0% | $447,555 |
| DYMON ASIA CAPITAL (SINGAPORE) PTE. LTD. | 0.03% | 80,400 | 0.07% | $319,992 |
Institutional Holders of NovaBridge Biosciences - Ordinary Shares, par value $0.0001 per share (Including Ordinary Shares Underlying American Depository Shares) (NBP) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 2,521 | $6,202 | -$145,440 | $2.46 | 2 |
| 2025 Q4 | 33,200,810 | $132,139,164 | +$14,644,437 | $3.98 | 57 |
| 2025 Q3 | 29,690,135 | $112,309,052 | +$77,501,715 | $3.78 | 42 |
| 2025 Q2 | 9,395,986 | $22,737,366 | +$2,030,864 | $2.42 | 32 |
| 2025 Q1 | 8,993,007 | $7,408,233 | -$2,236,666 | $0.82 | 29 |
| 2024 Q4 | 11,912,678 | $10,125,354 | -$4,196,499 | $0.85 | 27 |
| 2024 Q3 | 14,193,703 | $17,600,522 | -$1,644,775 | $1.24 | 27 |
| 2024 Q2 | 15,140,525 | $25,329,475 | +$4,917,141 | $1.67 | 37 |
| 2024 Q1 | 12,194,479 | $22,682,620 | -$591,267 | $1.86 | 38 |
| 2023 Q4 | 12,343,395 | $23,450,292 | -$3,932,021 | $1.90 | 43 |
| 2023 Q3 | 15,251,229 | $20,128,696 | -$8,412,218 | $1.32 | 46 |
| 2023 Q2 | 18,691,045 | $55,880,438 | -$6,382,969 | $2.99 | 46 |
| 2023 Q1 | 20,700,388 | $71,623,449 | -$16,502,335 | $3.46 | 51 |
| 2022 Q4 | 24,863,205 | $103,919,915 | -$23,835,362 | $4.18 | 63 |
| 2022 Q3 | 30,756,340 | $123,319,030 | -$78,451,098 | $4.01 | 69 |
| 2022 Q2 | 38,195,150 | $430,214,056 | -$43,072,457 | $11.30 | 91 |
| 2022 Q1 | 40,274,792 | $654,272,172 | -$2,809,989 | $16.24 | 112 |
| 2021 Q4 | 39,063,350 | $1,843,596,654 | +$49,692,681 | $47.39 | 127 |
| 2021 Q3 | 36,035,033 | $2,613,664,389 | +$445,184,584 | $72.49 | 140 |
| 2021 Q2 | 28,287,880 | $2,375,233,906 | +$495,487,800 | $83.95 | 133 |
| 2021 Q1 | 23,316,491 | $1,130,077,433 | +$490,958,954 | $48.47 | 78 |
| 2020 Q4 | 13,056,509 | $615,418,000 | +$200,018,636 | $47.15 | 63 |
| 2020 Q3 | 9,526,320 | $447,661,000 | +$236,962,427 | $47.03 | 48 |
| 2020 Q2 | 3,298,968 | $97,724,000 | -$2,617,263 | $29.93 | 19 |
| 2020 Q1 | 3,439,668 | $44,717,000 | +$44,717,000 | $13.00 | 15 |